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Dose kernel convolution (DK) methods have been proposed to
speed up absorbed dose calculations in molecular radionuclide
therapy. Our aim was to evaluate the impact of tissue density
heterogeneities (TDH) on dosimetry when using a DK method
and to propose a simple density-correction method. Methods:
This study has been conducted on 3 clinical cases: case 1, non-
Hodgkin lymphoma treated with 131I-tositumomab; case 2, a
neuroendocrine tumor treatment simulated with 177Lu-peptides;
and case 3, hepatocellular carcinoma treated with 90Y-micro-
spheres. Absorbed dose calculations were performed using
a direct Monte Carlo approach accounting for TDH (3D-RD),
and a DK approach (VoxelDose, or VD). For each individual
voxel, the VD absorbed dose, DVD, calculated assuming uniform
density, was corrected for density, giving DVDd. The average
3D-RD absorbed dose values, D3DRD, were compared with
DVD and DVDd, using the relative difference DVD/3DRD. At the
voxel level, density-binned DVD/3DRD and DVDd/3DRD were plotted
against r and fitted with a linear regression. Results: The DVD
calculations showed a good agreement with D3DRD. DVD/3DRD
was less than 3.5%, except for the tumor of case 1 (5.9%)
and the renal cortex of case 2 (5.6%). At the voxel level, the
DVD/3DRD range was 0%–14% for cases 1 and 2, and –3% to 7%
for case 3. All 3 cases showed a linear relationship between voxel
bin-averaged DVD/3DRD and density, r: case 1 (D 5 –0.56r 1 0.62,
R2 5 0.93), case 2 (D 5 –0.91r 1 0.96, R2 5 0.99), and case
3 (D 5 –0.69r 1 0.72, R2 5 0.91). The density correction im-
proved the agreement of the DK method with the Monte Carlo
approach (DVDd/3DRD , 1.1%), but with a lesser extent for the
tumor of case 1 (3.1%). At the voxel level, the DVDd/3DRD range
decreased for the 3 clinical cases (case 1, –1% to 4%; case 2,
–0.5% to 1.5%, and –1.5% to 2%). No more linear regression
existed for cases 2 and 3, contrary to case 1 (D 5 0.41r – 0.38,
R2 5 0.88) although the slope in case 1 was less pronounced.
Conclusion: This study shows a small influence of TDH in the
abdominal region for 3 representative clinical cases. A simple
density-correction method was proposed and improved the
comparison in the absorbed dose calculations when using our
voxel S value implementation.
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Molecular radionuclide therapy with 131I has been the
standard treatment for thyroid carcinoma for more than
50 y of clinical practice, but its treatment planning remains
based on a standard amount of activity defined according to
the nature of the residual tissues (1). Other targeted radio-
nuclide therapy (TRT) modalities have been developed
such as peptide receptor radionuclide therapy for neuroen-
docrine tumors (NET), radioimmunotherapy for antibody-
targeted tumors (e.g., non-Hodgkin lymphomas [NHL]),
and selective internal radiation therapy for hypervascular-
ized tumors, all with the potential for toxicity to normal
tissues. At this time, only the treatment regimen of NHL
with 131I-tositumomab requires patient-specific dosimetry.
Indeed, whole-body dosimetry is performed using a dosimetric
dose of 131I-tositumomab before the patient therapeutic ad-
ministration (2). However, most of the aforementioned TRT
modalities are still administered using a standard amount of
radioactivity or at best by adapting the amount of radioactivity
to the patient body weight or surface area (3,4).
Individual dosimetry can be implemented with a certain
level of personalization using 3-dimensional (3D) quantifica-
tion and standard absorbed dose coefficients (S value), which
are available from official MIRD publications (5–7) and can
be corrected for patient organ mass (8). Indeed, 3D quantifi-
cation methods using SPECT or PET can be implemented
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in clinical routine (9), using full iterative reconstruction,
including CT-based attenuation correction, as well as scatter
effect and collimator response compensations. The software
package OLINDA/EXM (10) provides the tools for organ
and suborgan dosimetry, including biologic data-fitting and
a comprehensive S value library. However, several limita-
tions have already been pointed out, mainly regarding the
impossibility of accounting for heterogeneous activity dis-
tribution within compartments (11) and the simplicity of the
spheric tumor model and tumor inclusion (12).
A much higher level of personalization can be obtained with
a fully 3D dosimetry for which each step of the dosimetry is
performed at the voxel level to allow editing of descriptive
statistics, dose–volume histograms (DVHs), and isodose
curves.
At this level of personalization, 2 options are available:
direct Monte Carlo simulation (MC) and dose kernel
convolution (DK).
Direct MC methods are based on generic MC codes such
as MCNP (Monte Carlo N-Particle) or EGS (Electron
g-Shower). They can take into account both radionuclide
and tissue density distributions, thus presumably leading
to an accurate absorbed dose distribution assessment. For
these reasons, MC methods are considered as the reference.
MC methods have been implemented in software tools,
such as 3D-RD (13), SIMDOS (14), and OEDIPE (15).
To speed up the computation, DK approaches have also
been proposed. The first was the dose point-kernel method
(16), which was later extended to voxel sources (dose
voxel-kernel) in MIRD pamphlet 17 (17) by the introduc-
tion of voxel S values (VSV). Absorbed dose calculation by
DK, either by dose point-kernel or dose voxel-kernel, can
take into account radionuclide distribution at the voxel
level, but rapid implementations using fast Fourier trans-
form or fast Hartley transform impose the use of an invariant
kernel and, thus, the assumption of uniform tissue density.
The DK methods are implemented in software tools such as
VoxelDose (18) and RMDP (19).
Direct MC simulations involve a higher computation time
than convolution approaches, particularly if one wants to
achieve a low statistical noise at the voxel level, making it
challenging for clinical practice. On the other hand, fast
implementations of DK approaches may be not suitable for
highly heterogeneous body regions such as the thorax or
bone sites. It has been shown that the differences between the
2 approaches in a homogeneous medium amount to no more
than small discrepancies in the average absorbed dose and at
the voxel level (11,20). Consequently, the DK approaches, in
cases for which the homogeneous tissue density assumption
can be made, are equivalent to direct MC computations.
Previous studies have discussed the impact of tissue hete-
rogeneities on the energy deposition of electrons, especially
on the backscatter effect (21–24). Indeed, the perturbations of
material interfaces were quantified in terms of backscatter
dose factor as described by Buffa et al. (23) for point sources.
The feasibility of using dose point-kernel scaling methods has
been shown by Janicki et al. (25) and Loudos et al. (26).
Furthermore, Furhang et al. (27) have included an equivalent
distance method in an MC approach.
The dosimetry of TRT is often focused in the abdomen
either for tumor localization (NETs, hepatic hypervascu-
larized tumors, or NHLs) or for organs at risk (liver, kidney,
or spleen). Indeed, in radioimmunotherapy, tumors can be
present in the abdominal region and toxicity can occur for
liver, kidneys, or spleen (28). In peptide receptor radionu-
clide therapy, tumors can be present in the abdomen, and
the kidney is an organ at risk because of the retention of
radiopeptides or radiometals (29). Also, the goal of selec-
tive internal radiation therapy is to control the tumor while
preserving the nontumoral liver (30).
Consequently, our goal was to study the influence of tissue
density heterogeneities (TDH) on abdominal 3D dosimetry
and in extend, the hypothesis of a homogeneous tissue
density. The use of simple density correction methods at the
voxel and organ level, similar to the organ mass correction
proposed in MIRD pamphlet 5 (8), was also investigated.
To this aim, 3 representative clinical cases were studied.
MATERIALS AND METHODS
Input Data
The 3 clinical cases included the following: case 1, a NHL
patient treated with unlabeled tositumomab, followed by 131I-tosi-
tumomab (Bexxar therapeutic regimen; GlaxoSmithKline); case 2,
a patient who had clinically suspected NETs and for whom dosim-
etry for possible therapy using 177Lu-peptides was simulated; and
case 3, a hepatocellular carcinoma (HCC) patient treated with
90Y-loaded microspheres.
For each case, the input data were the time-integrated activity
(TIA) map derived from the SPECT images and the density map
obtained from the CT scan and interpolated to the SPECT voxel
size. Both dose calculations (MC and DK) were based on the b–,
atomic electron, and photon components of 131I, 177Lu, and 90Y
decay spectra obtained from the RADTABS program (31).
3D-RD
The MC calculation was performed with the software tool 3D-RD
(32), based on the EGSnrc (EGS National Research Council Can-
ada) code. A more complete description of 3D-RD has been pre-
viously provided (13). Briefly, 10 million events were run using
8 parallel processes on a node of a Beowulf-class cluster (EGSnrc
MC software). The output values from the MC method given as
energy deposition distribution from the contributing components
per decaying particle were weighted for probability and TIA and
then converted to absorbed dose for each voxel by dividing by
the voxel mass. The absorbed dose D3DRD for each volume of
interest (VOI) as a whole was calculated by summing the energy
depositions and masses in the VOIs separately and then dividing
the VOI energy by the VOI mass. To take into account tissue
heterogeneity, tissue density derived from the patient’s CT data
was integrated in the MC calculation.
VoxelDose
The DK calculation, implemented using VSV, was performed
with the software tool VoxelDose (18). This implementation will
be referred to as VD. The VSVs were precalculated with MC code
MCNPX (33) at a fine voxel size, with the tissue medium set to
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soft tissue as defined by the International Commission on Radia-
tion Units and Measurements (r 5 1.04 gcm23) (34). The dose
calculation itself, as described by Dieudonné et al. (11), encom-
passes the resampling of the VSVat the voxel size of the TIA map
and the rapid convolution via a fast Hartley transform, giving the
absorbed dose DVD for each voxel of the TIA map.
Density Correction
To account for heterogeneous density distribution, a voxel den-
sity correction was applied to correct the absorbed dose within
each voxel DVDðx; y; zÞ with the voxel densities rðx; y; zÞ to obtain
DVDdðx; y; zÞ, using Equation 1. This implementation will be re-
ferred to as VDd.
DVDd

x; y; z

5 DVD

x; y; z

·
1:04
rðx; y; zÞ: Eq. 1
According to MIRD pamphlet 5 (8), an average organ density
correction was also applied to the average absorbed dose of each
target rT, to compensate for the differences between a uniform
density of 1.04 gcm23 and real density measurement from a vox-
elized density map rðx; y; zÞ, following Equation 2. This imple-
mentation will be referred to as VDd. This correction applies to
the electron (atomic and b–) and photon decay components and is
correct only for the local energy deposition of secondary electrons.
DVDd

rT

5 DVD

rT

·
1:04
rðrTÞ
: Eq. 2
Absorbed Dose Comparison
The absorbed dose maps computed with 3D-RD were used as
the reference. The comparison between the 3 VSV implementa-
tions (VD, VDd, and VDd) was performed in terms of absorbed
dose relative differences (DVD=3DRD 5
DVD 2 D3DRD
D3DRD
) at the organ–tumor
level and voxel level and in terms of DVH.
At the voxel level, density-binned DVD=3DRD and DVDd=3DRD
were plotted against the density rwithin VOIs and fitted with a linear
regression for absorbed doses above 1 Gy and density values above
0.90 gcm23 (0.96 gcm23 for case 3, for which the density values
were less dispersed). The analyses included 95.1% of the voxels in
the organs at risk (kidneys, liver, and spleen) for the radiopeptide
case, corresponding to 98.1% of the absorbed dose to those regions.
For the lymphoma case, 95.1% of the tumor voxels were used,
corresponding to 95.8% of the dose in the tumor. For the HCC case,
57.7% of the voxels in the liver were used, corresponding to 99.0%
of the dose. The discrepancy between these last 2 numbers is due in
large part to the fact that only the right lobe of the liver was treated
and due to localization of the activity uptake in the treated lobe.
The DVHs were computed in the tumor of case 1 and in tumor
and healthy liver for case 3.
Case 1: 131I-Tositumomab. Case 1 concerns a NHL patient with
a periaortal abdominal tumor who was imaged after the administra-
tion of 200 MBq of 131I-tositumomab as a tracer and subsequently
treated with the same radiopharmaceutical. This patient’s data have
previously been described and published (35). Abdominal SPECT/CT
images were acquired on a Phillips Precedence SPECT/CT scanner
(16-slice) at 48, 72, and 144 h after tracer administration. The SPECT
images were reconstructed using the QSPECT method (30 itera-
tions, 16 subsets per iteration) (36,37), based on the iterative ordered-
subsets expectation maximization algorithm with reconstruction-based
compensation for attenuation, scatter, and the collimator–detector re-
sponse function. The resulting matrix was 128 · 128 · 87 (3.91 ·
3.91 · 4.25 mm). The different reconstructed SPECT images were
then registered over time using a HERMES workstation. The activities
for the different voxels were fitted as a function of time with a hybrid
trapezoid–exponential fit and integrated to obtain the voxel TIAs. The
defined VOIs for this patient were the kidneys, spleen, liver, and tumor.
Case 2: 177Lu-Peptide. Case 2 concerns a patient with clinically
suspected NETs, examined at the University Hospital of Lausanne
and injected with 185 MBq of 111In-pentetreotide (OctreoScan;
Covidien) for diagnostic imaging. Three SPECT images of the ab-
dominal region were acquired at 4, 24, and 48 h after injection with
a 3-head g-camera (Triad; Trionix Research Laboratory, Inc.), using
a medium-energy collimator and 15% energy windows centered
at 171 and 245 keV. This patient’s data have also been described
and published previously (38). The SPECT images were recon-
structed and registered in a manner identical to that in case 1. The
resulting matrix was 128 · 128 · 128 (4.48 · 4.48 · 4.48 mm). The
voxelized activity was adjusted for the difference in physical half-
life between the pretherapeutic (111In, 67.3 h) and planned thera-
peutic (177Lu, 6.73 d) isotopes. The functional fit to the voxelized
activities was a simple exponential. VOI contours were drawn for
the kidneys, liver, and spleen. Furthermore, a distinction was made
between the renal cortices and medullae. This patient was not treated
because no tumors were evidenced in the 111In images. This case was
selected for its relevance to 177Lu renal dosimetry.
Case 3: 90Y-Microspheres. Case 3 concerns an HCC treated
with 1.0 GBq of 90Y-loaded resin microspheres. The data were
collected from the pretherapeutic procedure, which requires the
injection of 99mTc-macroaggregated albumin (MAA) (30), that is,
99mTc injected activity and a 99mTc-MAA SPECT/CT dataset. The
patient had a perfused volume of 99mTc-MAA of 1,500 cm3 and
a liver tumor of 714 cm3. The 99mTc-MAA SPECT/CT dataset
showed a potential 90Y gastric uptake. The SPECT/CT data were
acquired on a Symbia T2 g-camera (Siemens Healthcare) at the
nuclear medicine department of Beaujon Hospital. The data pro-
cessing has been described and published previously (39). The
reconstruction was performed using a 3D ordered-subsets expec-
tation maximization algorithm (6 iterations and 8 subsets) on
Syngo MI workplace (MIWP; Siemens Healthcare) with attenua-
tion, scatter, and nonuniform collimator response compensations.
The reconstructed SPECT voxel size was 4.8 · 4.8 · 4.8 mm. The
CT image was registered with MIWP. The TIA map was derived
from the 99mTc-MAA SPECT/CT dataset, assuming similar dis-
tributions within the liver for 90Y-microspheres and 99mTc-MAA
after adjustment was made for the difference in radionuclide phys-
ical half-life (64.1 vs. 6.02 h, respectively).
This study was approved by the local ethical committee, and all
patients signed a written informed consent form.
RESULTS
With the MC calculation, 2–3 h were required to gener-
ate 10 million events using a single cluster node (with 8
parallel processes), for each time point and decay type
(photon, b-particle, and atomic electron). On a desktop
computer, the calculation time for the DK method was
below 10 s for each case.
The comparison of the average absorbed dose to organs
and tumors is given for each case in Tables 1–3. Only 2
absorbed dose differences between D3DRD and DVD
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(DVD=3DRD) exceeded 5%. The highest difference from
the 3D-RD result was found for the tumor in case 1
(131I-tositumomab treatment), for which VD reported a lower
absorbed dose by 25.9%. The second value was found in
case 2 (177Lu-peptide treatment) for the renal cortex dosim-
etry (5.6%). Otherwise, the differences were less than 3.5%
for all organs and tumors within the 3 cases.
Transverse slices of the 3D absorbed dose maps com-
puted with 3D-RD and VoxelDose are given in Figure 1 for
each case. At the voxel level, the DVD=3DRD ranged from 0%
to 14% for cases 1 and 2 and from –3% to 7% for case 3. In
Figures 2A, 2C, and 2E, the density-binned DVD=3DRD plot-
ted against the density r for absorbed doses above 1 Gy are
presented. A linear relationship was found, showing that the
absorbed dose differences are strongly related to r for each
case: case 1: DVD=3DRD (%) 5 –55.6 r 1 61.9, R2 5 0.93;
case 2: DVD=3DRD (%) 5 –91.2 r 1 96.1, R2 5 0.99; and
case 3: DVD=3DRD (%) 5 –69.3 r 1 71.8, R2 5 0.91.
The use of density correction on VD computation globally
improved the agreement with 3D-RD. At the organ and tissue
levels, both VDd and VDd gave comparable results. Values of
DVDd=3DRD and DVDd=3DRD were less than 2%, except for the
tumor in case 1, for which relative differences of 23.6% and
3.1% were found, respectively. At the voxel level, DVDd=3DRD
ranges were smaller than the ones found for DVD=3DRD: –1% to
4% for case 1, –0.5% to 1.5% for case 2, and –1.5% to 2% for
case 3. Furthermore, a linear regression was found between
DVDd=3DRD and r only for case 1, with a smaller slope and cor-
relation coefficient than for DVD=3DRD (DVDd=3DRD (%)5 40.5
r – 38.0, R2 5 0.88) (Fig. 2B), whereas no linear relationship
was found for the other cases (R2 , 0.13).
The DVHs are presented for the D3DRD, DVD, and DVDd
calculations in Figure 3 (case 1) and Figure 4 for the liver
tumor and normal liver of case 3. For case 2, no DVHs were
computed because no tumor was present. The DVHs con-
firm the previous results with close curves for the three 3D
dosimetry calculations in case 3 (90Y-microspheres). For
case 1 (131I-tositumomab), the density correction did not
improve the agreement of the DVHs.
DISCUSSION
The purpose of this study was to evaluate the accuracy of
3D abdominal dosimetry, assuming the hypothesis of homo-
geneous tissue density when using a DK approach. A simple
density correction at the voxel level was also proposed and
evaluated. Our results show a small influence of TDH in the
abdominal region for the 3 representative clinical cases
studied. Nevertheless, the proposed density correction
method improved absorbed dose calculated with DK.
We chose to focus on the abdomen because of the small
differences in tissue density and because numerous admin-
istrations of TRT are of interest due either to the presence of
tumors or to the potential for normal-organ toxicity. Three rep-
resentative clinical cases were considered. Case 1 was a NHL
patient treated with 131I-tositumomab. Case 2 was a patient
with a clinically suspected NET treated with 177Lu-peptide.
Case 3 was an HCC patient treated with 90Y-microspheres.
For each case, the absorbed dose calculation was per-
formed with 2 approaches. First, a direct MC method im-
plemented in the software tool 3D-RD (32), taking into
account voxel density, was considered as the reference.
Second, we used DK, with a revision of the VSV method
TABLE 1
Average Absorbed Dose Comparison for Case 1
Average absorbed dose (Gy) and RD (%)
VD VDd VDd
Structure of interest TIA (MBq.s) Mass (g, with d(x,y,z)) Mass (g, with d 5 1.04) 3D-RD Gy % Gy % Gy %
Tumor 165 693 706 10.4 9.77 25.9 10.0 23.1 9.95 23.6
Liver (partial) 22.9 815 804 1.59 1.59 0.0 1.59 20.06 1.57 21.3
Spleen (partial) 6.52 173 172 1.87 1.86 20.5 1.87 0.21 1.85 21.2
Kidneys 46.3 594 612 3.86 3.73 23.5 3.88 20.52 3.84 20.42
d(x,y,z) 5 voxel density; d 5 kernel density.
TABLE 2
Average Absorbed Dose Comparison for Case 2
Average absorbed dose (Gy) and RD (%)
VD VDd VDd
Structure of interest TIA (MBq.s) Mass (g, with d(x,y,z)) Mass (g, with d 5 1.04) 3D-RD Gy % Gy % Gy %
Liver 621 2,220 2,251 7.05 6.90 –2.2 6.98 –1.1 6.99 –0.9
Spleen 437 318 325 33.5 32.4 –3.3 33.3 –0.7 33.2 –1.1
Renal cortex 585 503 528 28.4 26.8 –5.6 28.1 –1.0 28.1 –1.0
Renal medulla 60.7 129 133 11.9 11.5 –3.3 11.9 0.1 11.9 0.1
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(17). This method was implemented in the software tool
VoxelDose (or VD) (18), assuming a homogeneous density
distribution (r 5 1.04 gcm23). Both implementations (3D-
RD and VD) were previously compared in a homogeneous
soft-tissue medium for 90Y and 131I, with discrepancies
below 1% (11). Regarding the statistical equivalence of
both approaches, the MC simulations were done with 107
histories for each decay component, and the VSV kernels
were calculated with 109 histories (11). Therefore, the VD
calculation is statistically equivalent to an MC simulation
with 109 histories per voxel. Although the statistical uncer-
tainties between 3D-RD and VD are not equivalent, the
voxel-based comparison is not affected, because the absorbed
dose differences were binned (toward density) before being
plotted against density.
The calculation time with MC was much longer than
when using our VD method, but this should not hide the
fact that VSVs require long prior calculations and an al-
gorithm to be adapted to the voxel size of the g-camera.
Furthermore, with DK in general, and VSV in our case, it is
not possible to integrate the effect of TDH on the energy
deposition. Therefore, a postcalculation density correction
is proposed and investigated. Its principle is to correct the
absorbed dose for each voxel by scaling it with the real
density values derived from CT data. This correction would
not adjust the fluency perturbations of primary particles
(photons or electrons) but only the local energy deposition
of secondary charged particles (electrons).
The organ and tumor level comparison between 3D-RD
and VD shows a limited impact of tissue heterogeneities,
with relative differences on the average absorbed dose,
DVD=3DRD, ranging from 25.9% to 1.7% for the 3 studied
clinical cases (Table 1). The results are in agreement with
previous results obtained by Buffa et al. (23) and confirm
our assumptions.
Slices of the 3D absorbed dose maps computed with 3D-
RD and VD show similar aspects (Fig. 1). Because of the
statistical nature of MC simulations (3D-RD), the corre-
sponding absorbed dose maps are less smoothed than the
ones obtained with the VD method.
At the voxel level, the comparison between 3D-RD and
VD showed a DVD=3DRD range of 0% to 14%. Furthermore,
a linear relationship between DVD=3DRD and the density r
was found for the 3 clinical cases studied, with R2 values
over 0.90 and slopes with absolute values higher than 50
(291.2 to 255.6). This finding indicated a dependence of
DVD=3DRD on tissue density at the voxel level, although the
impact of this dependence and tissue heterogeneities on
abdominal dosimetry is likely to be small given the relatively
TABLE 3
Average Absorbed Dose Comparison for Case 3
Average absorbed dose (Gy) and RD (%)
VD VDd VDd
Structure of interest TIA (MBq.s) Mass (g, with d(x,y,z)) Mass (g, with d 5 1.04) 3D-RD Gy % Gy % Gy %
Tumoral liver 196 749 743 38.2 38.8 1.7 38.5 0.8 38.5 0.8
Nontumoral liver 86.1 1,970 1,954 6.55 6.7 1.6 6.60 0.8 6.60 0.8
Stomach wall 1.29 226 230 0.86 0.85 –1.5 0.86 –0.1 0.86 0.1
FIGURE 1. Case 1: images of NHL treated with 131I-tositumomab.
Transverse slice of absorbed dose calculated with 3D-RD (A) and
VoxelDose (B) without density correction (VD) is shown. Main differ-
ences between both absorbed dose maps are due to MC statistical
fluctuations (A). Case 2: simulation of 177Lu-peptide. Transverse
slice of absorbed dose calculated with 3D-RD (C) and VoxelDose
(D) without density correction (VD) is shown. Case 3: HCC treated
with 90Y-microspheres. Transverse slice of absorbed dose calcu-
lated with 3D-RD (E) and VoxelDose (F) without density correction
(VD) is shown. Dashed lines represent tumor boundaries.
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uniform distribution within the abdomen. DVHs confirm this
notion because they show that the density distributions are
heavily weighted toward a few average-density bin values;
these histograms are given as supplemental Figures 1–3
(supplemental materials are available online only at http://
jnm.snmjournals.org).
The density corrections at the voxel and organ levels
improved the dose calculation with VD, with DVDd=3DRD
ranging from 23.1% to 0.8% and DVDd=3DRD ranging from
23.6% to 0.8%. The major improvement concerns case 2,
with DVD=3DRD initially ranging from 25.6 to 22.2% and
DVDd=3DRD ranging from21.1% to 0.1% after correction. In
contrast, the density correction for case 3 is of limited in-
terest; because of low relative discrepancies without any
correction (DVD=3DRD ranging from 21.5% to 1.7%), the
relative differences with density correction DVDd=3DRD were
below 1%, which is on the order of the statistical uncer-
tainty of the 3D-RD MC simulation values used as a com-
parison. Although the MC statistical uncertainties on individual
voxel absorbed doses are relatively high (root-mean-square
values for the voxel uncertainties are 6.5%, 4.7%, and 5.0%
for the 3 cases), the uncertainty on the binned values are
FIGURE 2. Case 1: NHL treated with 131I-
tositumomab. Linear correlation between
density-binned average absorbed dose dif-
ferences DD and density r, for absorbed
doses above 1 Gy and r $ 0.9 gcm–3, is
shown. (A) DD between 3D-RD and Voxel-
Dose with homogeneous density (VD). (B)
DD between 3D-RD and VoxelDose with
density correction (VDd). Case 2: simulation
of 177Lu-peptide. Linear correlation between
density-binned DD (average absorbed dose
differences) and r (density), for absorbed
doses above 1 Gy and r $ 0.9 gcm23, is
shown. (C) DD between 3D-RD and VD.(D)
DD between 3D-RD and VDd. Case 3:HCC
treated with 90Y-microspheres. Linear corre-
lation between density-binned DD (average
absorbed dose differences) and r (density),
for absorbed doses above 1 Gy and r $
0.96 gcm23, is shown. (E) DD between
3D-RD and VD. (F) DD between 3D-RD
and VDd.
FIGURE 3. Case 1: NHL treated with 131I-tositumomab. DVH in
tumor calculated by 3D-RD, VoxelDose with homogeneous density
distribution (VD), and with density correction (VDd).
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much lower (the maximum bin uncertainties due only to
MC statistics are 0.7%, 0.4%, and 0.5%).
The density correction at the voxel level improved the
agreement between 3D-RD and VD at the voxel level. Indeed,
the voxel absorbed dose relative difference DVDd=3DRD range
was reduced to –1.5% to 4%. Furthermore, no relationship
was found between the relative difference DVDd=3DRD and r
for 177Lu-peptide and 90Y-microsphere cases (Figs. 2D and
2F), whereas a linear relationship still existed between
DVDd=3DRD and r for the
131I-tositumomab case but with
a smaller slope than with DVD=3DRD (40.5 vs. 255.6, re-
spectively; Figs. 2A and 2B) and a smaller correlation co-
efficient (0.88 vs. 0.93, respectively). This result can be
explained by the fact that the proposed density correction
is more effective for nonpenetrating particles and thus for
preponderant b– emissions (90Y and 177Lu). When looking
at Figures 2A, 2C, and 2E, the difference between VD and
MC for r 5 1.04 gcm23 is near zero for case 3, 1% for
case 2, and 4% for case 1, meaning that the influence of
tissue heterogeneities does not depend only on the local
energy deposition for these 2 latter cases. Indeed, the yield
of the photon component is greater for 131I (yield, 1.0)
than 177Lu (yield, 0.17) and null for 90Y. For a comprehen-
sive density correction, the cross-dose component would
have to be treated separately as it is more affected by
density heterogeneities at a larger scale (tissue, suborgan).
Our results are valid in the conditions we met—that is,
the abdominal region and radionuclides with major dose
contribution coming from the electron emissions (atomic
and b–). The comparison was done with specific MC and
DK implementations, namely 3D-RD and VoxelDose, re-
spectively. 3D-RD was chosen as the gold standard with the
advantage of being well established, with a history of clin-
ically relevant publications.
Further studies will have to be undertaken with different
conditions for any extension of these results to other treat-
ment localizations, radionuclides. Additionally, the imple-
mentation of scaling methods that were proposed for
internal dosimetry (25–27) could be investigated in other
conditions—that is, with a major photon emission compo-
nent or with sites in the thoracic region or bone.
CONCLUSION
There is a small but significant influence of tissue density
heterogeneity on the absorbed dose calculation in the
abdominal region for radionuclides with a preponderant
b-emission (i.e., 131I, 177Lu, and 90Y). A simple density
correction at the voxel level was proposed for DK methods,
allowing improvement of the absorbed dose calculation.
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